A Study of GV20-0251 in Advanced or Refractory Solid Tumors

This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.

Trial Details

NCT ID
NCT07106827
Phase
PHASE1
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • GV20-0251
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Before conducting any study-specific procedures, voluntarily sign an informed consent form.
  • Be able and willing to participate throughout the entire study period and comply with study procedures.
  • participants ≥18 years of age
  • Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy (Refractory or intolerant to stan…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →